Introduction {#s1}
============

Over the past 40 years, pharmacology, immunology, and cell biology have contributed enormously to understanding the mechanisms of diseases with allergic etiologies, viz. atopic dermatitis, allergic rhinitis, and much of asthma. The pharmacologic contribution to this research effort has created a wealth of new molecular and biologic entities that have enjoyed success as experimental tools. However, for new entities acting upon unprecedented targets, this drug discovery enterprise has largely failed when assessed against the metric of clinical success. These endeavors have revealed the inherent weakness in treating the effects rather than causes of disease and have demonstrated convincingly the difficulties faced when making focused interventions against strategic effector mechanisms that are backed up by multiple redundancies. Indeed, the supremacy of inhaled corticosteroids as a standard of care for asthma highlights the benefits of a broad spectrum of action, but despite this, discrete targets in downstream effector pathways continue to attract attention. The more recent focus on interventions based on new biologic entities, such as monoclonal antibodies directed against interleukin 5 (IL-5), the shared IL-4/IL-13 receptor *α*-subunit, or thymic stromal lymphopoietin (TSLP), has demonstrated that success with new approaches is certainly feasible when patients are rigorously stratified for treatment. Nevertheless, the overarching philosophy in these newly approved or emerging biologic approaches remains directed at downstream effectors, and inevitably, the reminders of the high risk of failure associated with this level of intervention are ever present because not all anticytokine development programs have enjoyed positive outcomes in asthma. This raises strategic questions for the design of new approaches to these diseases, and among the most challenging topics are the identification of tractable new targets and the future that remains for small-molecule design in an era when biologics are in the limelight.

Encouragingly, alternative philosophies have delivered success, as demonstrated by omalizumab, the monoclonal antibody therapy which depletes circulating IgE to eventually reduce the amount of antibody bound to high-affinity IgE receptors on mast cells. The development of omalizumab represented a significant change from a focus on symptom amelioration to an upstream intervention potentially capable of disease modification. However, among other significant issues, biologic therapies such as omalizumab pose significant reimbursement challenges which are problematic for patient access to treatment in chronic diseases affecting large populations.

From a theoretical perspective, an ideal intervention would target a root cause of allergic disease, namely, allergens themselves. This is, of course, partly the basis of the long-standing practice of allergen-specific immunotherapy. For small-molecule interventions, this root-cause approach has been generally viewed as an unattainable goal: there are many allergens in the environment, many of which remain poorly characterized, and exactly why they are allergenic---that is, break immune tolerance and promote IgE-directed immune responses---has, until relatively recently, been a surprisingly unfashionable topic in allergy. However, progress in the characterization of allergens has shed new light on the molecular basis of allergenicity, and this has coincided with a renaissance of interest in innate immunity. This creates the possibility of making interventions at critical checkpoints in these pathways to prevent the development of allergic disease. In particular, it is now possible to design an approach to target a major asthma trigger at root-cause level, with the advantage that this circumvents concerns about the chronic consequences of blocking checkpoints which are of fundamental importance to immunity. Unlike allergen-specific immunotherapy, an important advantage of this new line of attack is the prevention of innate immune responses which are the engine of allergy development. The purpose of this review is to examine the biologic mechanisms by which a major house dust mite (HDM) allergen triggers allergic disease, and describe the design of an intervention to specifically neutralize this activity. The choice and nature of the target are unprecedented and may be unfamiliar to those outside the immediate field; therefore, as an aid to interested newcomers, we also describe the historical background to HDM allergens and allergic disease, their clinical significance, and a brief overview of the complete spectrum of denominated HDM allergens.

HDM Allergens and Disease {#s2}
=========================

House dust is a complex mixture of biologically diverse components from various sources with properties that render it inhalable by humans. House dust as a cause of allergic disease was first recognized in 1921 by the American physician Richard Kern, who observed that many patients with rhinitis or asthma had positive skin reactions to extracts of dust from their own homes. This idea was elaborated further in the following two decades by Willem Storm van Leeuwen, Professor of Pharmacology and Director of the Pharmacotherapeutic Institute at the University of Leiden, who proposed that the cause of asthma could be the presence of mites in house dust. However, conclusive proof remained elusive until 1967, when Spieksma and Voorhorst and their colleagues ([@B141]) established that *Dermatophagoides pteronyssinus* was an important source of indoor allergens---a linkage which we now regard as intuitive, but which at the time was received with fierce skepticism from many allergists. It is now recognized that HDMs such as *D. pteronyssinus* or *Dermatophagoides farinae* form the single most important indoor allergen source associated with asthma in temperate climates and lead to the development of high-titer allergen-specific IgE. The growth in sensitization of human populations is, in part, promoted by indoor, sedentary, affluent lifestyles and the creation of warm, humid, draft-free habitation and working conditions which provide optimal growth conditions for HDMs. Consequently, many people are extensively exposed to HDMs with the result that allergic diseases triggered by indoor allergens are major healthcare problems with a significant socioeconomic impact.

Substantial evidence associates allergic conditions such as asthma, chronic rhinitis, atopic dermatitis, and, less frequently, conjunctivitis with exposure to HDM or other indoor allergens ([@B110]; [@B91], [@B92]; [@B112]; [@B37]; [@B89]; [@B113]; [@B90]; [@B93]). Data from longitudinal investigations suggest that the development of sensitization to HDM occurs before polysensitization ([@B109]; [@B96]), that is, the development of allergy to other triggers, a phenomenon which occurs in ∼50%--80% of people ([@B13]). At first, this ordering of events in polysensitization seems puzzling until it is recognized that the bioactivity of certain allergens makes them unusually potent stimulants and providers of collateral immune priming on which other allergens depend. In this regard, certain HDM proteins function broadly as bioinitiators as well as simply being allergenic.

HDMs are small arthropods, ∼250 *µ*m in length, related to spiders and scorpions. Many mite species are found in house dust, but the pyroglyphid family dominates in most areas of the world (e.g., *D. pteronyssinus, D. farinae*, and *Euroglyphus maynei*). In the tropics, allergy to *Blomia tropicalis* may also be prevalent. Dust mites live on a diet of exfoliated human skin flakes and other biodebris. Existing on this diet means that HDMs have digestive enzymes which can process tough structural proteins. Food waste is excreted, together with the digestive enzymes, in pellets which are of a respirable aerodynamic diameter (10--30 *µ*m). As described later, these excreted digestive enzymes are significant because they are allergenic with a bioactivity profile which provides them with the ability to promote sensitization to themselves and unrelated inhalant allergens, regardless of source. Sensitization to HDM allergens occurs through inhalation of their fecal pellets, which impact on the airway epithelium where airway surface liquid triggers the release of the pellet contents, resulting in a high concentration of allergen at the site of deposition. Sensitization by inhalation may also be the case in people who develop atopic dermatitis rather than allergic conditions of the airways, although in established dermatitis, any ensuing allergic responses are more likely to result from skin contact.

 {#s3}

### Allergen Nomenclature. {#s4}

Allergens are classified according to a system devised in 1984 by the Allergen Nomenclature Sub-Committee, which was established jointly by the World Health Organization and the International Union of Immunologic Societies. The systematic naming of allergens takes the accepted binomial nomenclature of the source and uses the first three letters of the genus combined with the first one or two letters of the species name followed by an Arabic numeral reflecting the order in which the allergen was isolated or its clinical importance (or, in reality, a hybrid of both). This numbering allows the denomination of allergens by group. In the case of *Dermatophagoides pteronyssinus*, the systematic naming takes the form Der p X, where X is the group number, and this is replicated in similar allergens from related species. Thus, HDM cysteine protease allergens from *D. pteronyssinus*, *D. farinae*, *Euroglyphus maynei*, and *Blomia tropicalis* are known individually as Der p 1, Der f 1, Eur m 1, and Blo t 1, respectively; collectively as the group 1 HDM allergens; or as the HDM cysteine proteases. Denomination is further resolved to accommodate the allelic variation in proteins, which gives rise to isoallergens. Those allergens from the same source species with \>67% sequence identity are denoted using suffixes which may be up to four digits in length according to the complexity of the isoallergenic variations (e.g., Der p 1.0101, Der p 1.0102, etc.). As an additional refinement, it is sometimes necessary to denote whether allergens are in their native (n) forms or are products of recombinant protein engineering (r). Recombinant allergens differ most notably in protein glycosylation, which is usually due to the need to modify potential glycosylation sites, e.g., to prevent hyperglycosylation of proteins expressed in yeast, an expression system which is often favored because it generally provides correct protein folding and thus mimics conformational epitopes and other biologic characteristics seen in native allergens. Whereas some glycosylation changes may have neutral or little impact on bioactivities such as the protease behavior of Der p 1 ([@B138]), they are more relevant to the processing of allergens by antigen-presenting cells. Thus, the prefixes n and r, respectively, may be appended (e.g., nDer p 1, rDer p 1).

More than 30 groups of HDM allergens have now been denominated, making HDMs probably the single largest source of allergens to which humans are exposed. These allergens do not, however, have equal clinical importance because a clear serodominance is observable for those belonging to groups 1 and 2. A summary of HDM allergens and their properties is provided in [Table 1](#T1){ref-type="table"}. Molecular biology, genomics, and bioinformatics have played key roles in the elucidation of these groups, particularly in predicting their functional properties in the host---information which provides important insights into why those molecules behave as allergens in humans. Further information about the characteristics of these allergen groups can be obtained by using the GenBank and UniProt accession codes listed in [Table 1](#T1){ref-type="table"}.

###### 

Group denominations of HDM allergens, with exemplars, and their bioactivity profiles based on bioinformatics predictions and/or empirical observations

The list omits storage mite species exemplars of the subclass Acari, although in many cases their allergens show the same grouping and characteristics as the HDM allergens. Exemplar GenBank and UniProt accession codes of the listed allergens are provided for supporting literature references and bioinformatics substantiation (e.g., by hyperlink to simple modular architecture research tool "SMART"), but codes for isoallergenic variants are omitted for brevity.

  HDM Allergen Group Exemplars   Molecular Mass                               Known or Predicted Bioactivity                                                                                                                                                          GenBank/EMBL                                  UniProt
  ------------------------------ -------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- -----------------------------------------------
                                 *kDa*                                                                                                                                                                                                                                                                              
  Group 1, e.g., Der p 1         25 (39 Blo t 1)                              Cysteine protease                                                                                                                                                                       U11695                                        P08176
  Der f 1                        AB03496                                      Q58A71                                                                                                                                                                                                                                
  Eur m 1                        AF047610                                     P25780                                                                                                                                                                                                                                
  Der m 1                        ---                                          P16312                                                                                                                                                                                                                                
  Blo t 1                        AF277840                                     Q95PJ4                                                                                                                                                                                                                                
  Group 2, e.g., Der p 2         14                                           NPC2 family; MD-2--related protein, lipid binding, binds LPS                                                                                                                            AF276239                                      P49278
  Der f 2                        D10447                                       Q00855                                                                                                                                                                                                                                
  Eur m 2                        AF047613                                     Q9TZZ2                                                                                                                                                                                                                                
  Blo t 2                        AY288141                                     Q1M2P1                                                                                                                                                                                                                                
  Group 3, e.g., Der p 3         25                                           Trypsin                                                                                                                                                                                 U11719                                        P39675
  Der f3                         D63858                                       P49275                                                                                                                                                                                                                                
  Eur m3                         AF047615                                     O97370                                                                                                                                                                                                                                
  Blo t 3                        AY291323                                     A1KXI1                                                                                                                                                                                                                                
  Group 4, e.g., Der p 4         60                                           Amylase                                                                                                                                                                                 AF144060                                      Q9Y197
  Der f 4                        KM016832                                     A0A089FLV3                                                                                                                                                                                                                            
  Eur m 4                        AF144061                                     Q9Y196                                                                                                                                                                                                                                
  Blo t 4                        AY291324                                     A1KXI2                                                                                                                                                                                                                                
  Group 5, e.g., Der p 5         14                                           Function unknown; ligand-binding protein?                                                                                                                                               S76337                                        P14004
  Blo t 5                        U59102                                       O96870                                                                                                                                                                                                                                
  Group 6, e.g., Der p 6         25                                           Chymotrypsin                                                                                                                                                                            ---                                           P49277
  Der f 6                        AF125187                                     P49276                                                                                                                                                                                                                                
  Blo t 6                        AY291325                                     A1KXI3                                                                                                                                                                                                                                
  Group 7, e.g., Der p 7         26--31                                       Bactericidal permeability-increasing like protein of unknown function; belongs to the juvenile hormone binding family of proteins found in insects; may have lipid-binding properties   U37044                                        P49273
  Der f 7                        S80655                                       Q26456                                                                                                                                                                                                                                
  Blo t 7                        MF740745                                     ---                                                                                                                                                                                                                                   
  Group 8, e.g., Der p 8         27                                           Glutathione *S*-transferase                                                                                                                                                             S75286                                        P46419
  Der f 8                        KC305499                                     L7V2G7                                                                                                                                                                                                                                
  Blo t 8                        GQ398117                                     C8CGT7                                                                                                                                                                                                                                
  Group 9, e.g., Der p 9         29                                           Collagenase-like serine protease                                                                                                                                                        AY211952                                      Q7Z163
  Group 10, e.g., Der p 10       36                                           Tropomyosin                                                                                                                                                                             Y14906                                        O18416
  Der f 10                       D17682                                       Q23939                                                                                                                                                                                                                                
  Blo t 10                       EU106615                                     A7XZI4                                                                                                                                                                                                                                
  Group 11, e.g., Der p 11       103                                          Paramyosin                                                                                                                                                                              AY189697                                      Q6Y2F9
  Der f 11                       AF352244                                     Q967Z0                                                                                                                                                                                                                                
  Blo t 11                       AF525465                                     Q8MUF6                                                                                                                                                                                                                                
  Group 12, e.g., Blo t 12       14                                           Possible chitinase; shows homology with Der f 15 due to chitin-binding domain                                                                                                           U27479                                        Q17282
  Group 13, e.g., Der p 13       15                                           Fatty acid--binding protein                                                                                                                                                             HM560018                                      E0A8N8
  Der f 13                       AY283293                                     Q1M2P5                                                                                                                                                                                                                                
  Blo t 13                       U58106                                       Q17284                                                                                                                                                                                                                                
  Group 14, e.g., Der p 14       177                                          Vitellogenin or lipophorin                                                                                                                                                              AF373221                                      Q8N0N0
  Der f 14                       D17686                                       Q94507                                                                                                                                                                                                                                
  Eur m14                        AF149827                                     Q9U785                                                                                                                                                                                                                                
  Group 15, e.g., Der p 15       98, 109[*^a^*](#t1n1){ref-type="table-fn"}   GH18 superfamily chitinase; shows homology with mite group 18.                                                                                                                          DQ078741                                      Q4JK69
  Der f 15                       AF178772                                     Q9U6R7                                                                                                                                                                                                                                
  Group 16, e.g., Der f 16       53                                           Gelsolin/villin                                                                                                                                                                         AF465625                                      Q8MVU3
  Group 17, e.g., Der f 17       30                                           Calcium-binding protein                                                                                                                                                                 ---                                           ---
  Group 18, e.g., Der p 18       60                                           GH18 superfamily chitinase; homologous with group 15                                                                                                                                    DQ078739                                      Q4JK71
  Der f 18                       AY093656                                     Q86R84                                                                                                                                                                                                                                
  Group 19, e.g., Blo t 19       7                                            Antimicrobial peptide homology                                                                                                                                                          KF771884                                      W5RZ24
  Group 20, e.g., Der p 20       40                                           Arginine kinase                                                                                                                                                                         EU684970                                      B2ZSY4
  Der f 20                       KM009994.1                                   ---                                                                                                                                                                                                                                   
  Group 21, e.g., Der p 21       14                                           Function unknown; shows homology with group 5 allergens                                                                                                                                 DQ354124                                      Q2L7C5
  Der f 21                       KF732965.1                                   B2GM84                                                                                                                                                                                                                                
  Blo t 21                       DQ788679                                     A7IZF1                                                                                                                                                                                                                                
  Group 22, e.g., Der f 22       17                                           Shows homology with group 2 mite allergen; belongs to MD-2--related lipid recognition domain family; implicated in lipid binding                                                        DQ643992                                      A5X5X4
  Group 23, e.g., Der p 23       14--19                                       Unknown function; shows homology with peritrophin-A domain and contains a chitin-binding domain                                                                                         EU414751.1                                    L7N6F8
  Der f 23                       KU166910                                     ---                                                                                                                                                                                                                                   
  Group 24, e.g., Der p 24       13                                           Ubiquinol-cytochrome c reductase binding protein-like protein                                                                                                                           KP893174                                      A0A0K2GUJ4
  Der f 24                       KC669700                                     M9RZ95                                                                                                                                                                                                                                
  Group 25, e.g., Der f 25       34                                           Triosephosphate isomerase                                                                                                                                                               KC305500.1                                    L7UZA7
  Group 26, e.g., Der f 26       18                                           Myosin alkali light chain                                                                                                                                                               KM009996[*^b^*](#t1n2){ref-type="table-fn"}   A0A088SAG5[*^b^*](#t1n2){ref-type="table-fn"}
  Group 27, e.g., Der f 27       48                                           Serpin--trypsin inhibitor                                                                                                                                                               AIO08851                                      ---
  Group 28, e.g., Der f 28       70                                           Heat shock protein                                                                                                                                                                      KC305502                                      L7V065
  Group 29, e.g., Der f 29       16                                           Peptidyl-prolyl *cis-trans* isomerase (cyclophilin)                                                                                                                                     AY283280.1                                    A1KXG2
  Group 30, e.g., Der f 30       16                                           Ferritin                                                                                                                                                                                KC305503                                      L7UZ91
  Group 31, e.g., Der f 31       15                                           Cofilin, actin binding protein                                                                                                                                                          KM010014                                      A0A088SAY1
  Group 32, e.g., Der f 32       35                                           Secreted inorganic pyrophosphatase                                                                                                                                                      KM009993                                      A0A088SCP3
  Group 33, e.g., Der f 33       52                                           *α*-tubulin                                                                                                                                                                             KM010005                                      A0A088SV41
  Group 34, e.g., Der f 34       16                                           Enamine/imine deaminase                                                                                                                                                                 LC120618                                      A0A1J1DL12
  Group 35, e.g., Der f 35       14                                           MD-2--related protein homologous with group 2                                                                                                                                           LC175222                                      A0A1W7HBY9
  Group 36, e.g., Der p 36       42                                           Function unknown; contains a C-terminal C2 domain (pfam00168) associated with signal transduction                                                                                       KY465507                                      A0A291KZD3
  Der f 36                       KY465506                                     A0A291KZC2                                                                                                                                                                                                                            
  Group 37, e.g., Der p 37       30                                           Peritrophic-like protein domain                                                                                                                                                         MG520330[*^c^*](#t1n3){ref-type="table-fn"}   ---

EBML, European Molecular Biology Laboratory.

Glycosylated forms of 63-kDa protein predicted by DNA sequence.

Note that GenBank/European Bioinformatics Institute and UniProt incorrectly designate this as a group 30 allergen. Definitively, it is a group 26 allergen as designated by the Allergen Nomenclature Sub-Committee of the World Health Organization and International Union of Immunologic Societies. Please refer to <http://www.allergen.org/viewallergen.php?aid=815> for further information.

Accession not yet published.

Group 1 HDM Allergens as a Drug Design Target {#s5}
=============================================

As clan CA, C1 family cysteine proteases, group 1 HDM allergens have a basic structure, comprising a substrate-binding groove separating two globular domains, which is archetypally defined by the extensively studied representatives, papain, actinidin, and cathepsin K. Proteolytic latency of the HDM allergens is maintained in the proenzyme form because the prodomain occludes the catalytic center of the enzyme while covalently tethered to the rest of the molecule, and in so doing, it masks some IgE epitopes. This results in proteolytically latent HDM allergens being less immunogenic than their catalytically competent mature forms ([@B117]). Differences in prodomain structure between the HDM allergens and cathepsins have functional implications which place them in an identifiable subfamily of C1 enzymes ([@B139]). The group 1 allergen prodomains from *Dermatophagoides* species comprise 80 amino acids arranged as four *α*-helices. Thus, they can be distinguished from cathepsins K, L, and S, in which the longer propieces comprise only three *α*-helices and contain a conserved "ERFNIN" motif \[EX~3~RX~2~ (I/V)FX~2~NX~3~IX~3~N\] that is absent in the HDM allergens ([@B139]). Other cathepsins, notably cathepsin B, have prodomains which lack a further *α*-helix and which are shorter than the HDM allergens. In cathepsins, untethered propeptide units generally behave as regulators of their cognate proteases, but this seems not the case in Der p 1 (and, by inference, other group 1 HDM allergens) where maturation of the protease results in rapid degradation of the propiece and unconstrained enzymatic activity ([@B139]). The corresponding group 1 allergen Blo t 1 of *B. tropicalis*, found only in tropical regions, represents an intermediate case between the more pervasive *Dermatophagoides* group 1 allergens and cathepsins. At the time of writing, catalytic competence of Blo t 1 is only inferred from alignment of its putative catalytic residues (C^119^ H^263^ N^283^) with Der p 1, and formal proof of the enzymatic activity of unambiguously pure allergen is awaited. It differs from its *Dermatophagoides* counterparts in sharing only ∼30% sequence identity overall and having a modified ERFNIN motif (ERFQVN), which may indicate that its prodomain could remain a potential inhibitor after maturation, restricting its behavior. In that regard, it is noteworthy that although Blo t 1 is clearly a major allergen of *B. tropicalis*, it is not obviously serodominant, unlike the group 1 HDM allergens. It is tempting to speculate that the lack of serodominance may be related to inferences that can be drawn about control of its proteolytic capacity.

Of numerous difficulties encountered in studying the biology of allergens, a fundamental challenge is their purification from the complex mixture of bioactive materials with which they are normally associated. Although such extraneous materials may have deep relevance to host immune responses and disease development, they can be serious confounding factors when investigating functions and mechanisms at the molecular level. A pertinent example was the claim, which has enjoyed a persistence in some literature, that Der p 1 is a multifunctional protease with both cysteine and serine protease activities ([@B53]). It is now clear that this is incorrect: no evidence for this notion exists within the crystal structure of Der p 1, and studies with native and recombinant Der p 1 in the presence of highly selective inhibitors provide no functional support. The likeliest explanation for the misleading claim is that the native Der p 1 preparation studied by those researchers was contaminated with serine peptidase allergens because native Der p 1 prepared by a strategy to rigorously eliminate such contamination fails to degrade the chymotrypsin substrate *N*-succinyl-AAPF-*p*-nitroanilide. In contrast, both trypsin and Der p 1 degrade *N*-Bz-FVR-*p*-nitroanilide, but whereas Der p 1 is inhibited by (S)-3-((S)-2-((S)-2-benzamido-3-methylbutanamido)propanamido)-2-oxoheptyl-2,6-bis(trifluoromethyl)benzoate (ADZ 50,000), it is not affected by a generic serine peptidase inhibitor, aminoethylbenzenesulfonyl fluoride, which blocks the action of trypsin (our unpublished data).

The cleavage specificity of Der p 1 has been evaluated in peptide sequences from suspected target proteins and by library screening campaigns. Substrates in a combinatorial library of general formula Abz-1-2-3-4-Y(NO~2~)-D-NH~2~, with cleavage between residues 3 and 4, revealed the following preferences for Der p 1: 1) V\>A,Q,L,F; 2) A\>\>Q or K; 3) L, J, or A\>S; and 4) S. Noting that J is an isostere of K, these findings are similar to the results of screening crude HDM extracts in a different combinatorial library where the preferences for the S~1~-S~4~ pockets were K, A, V, and J, respectively. A more recent campaign using phage display has proposed a preference for K/R,V,L/V,V,V for the S~1~-S~5~ pockets and used a bioinformatics approach to predict potential cellular substrates, some of which have not previously been revealed by hypothesis-driven investigation ([@B58]). Although informative about the selectivity or promiscuity of enzyme pockets, this information does not, of course, translate directly into obvious function or provide immediate chemical design solutions for inhibitor discovery. Potential substrates may be clandestine in cellular reality and, therefore, of marginal biologic significance. Conversely, apparently disfavored substrates may be presented in ways which encourage attack or whose cleavage initiates amplification mechanisms which transform the wider biologic significance of the target. For inhibitor design, an appreciation of the binding site topology taken together with substrate preferences is merely a first step in the creation of developable chemical entities as opposed to tool compounds whose value is restricted.

Examination of the structure of Der p 1 determined from crystals of isoallergen Der p 1.0105 reveals the presence of three disulphide bridges (C^84^-C^197^, C^111^-C^151^, and C^145^-C^183^) and suggests that the amino acid residues surrounding the substrate-binding groove, with its characteristic catalytic triad of C^114^, H^250^, and N^270^, are well conserved. The clear implication is that substrate preferences are consistent among isoallergens in a single species of HDM and between homologous allergens in different HDM species. This is supported by enzyme kinetic and inhibitor data (our unpublished data) and structural comparison of the active sites of Der p 1 and Der f 1, where substitution of R^231^ in Der p 1 by Q^232^ is the most notable difference.

High-resolution structural data allow the binding pockets of Der p 1 to be compared with off-target enzymes which have the potential to constitute selectivity nuisances in drug design. An empirical observation made in early discovery research was that nonoptimized inhibitors of Der p 1 were effective inhibitors of cathepsin B but showed good selectivity over cathepsins S and K. We believe that the selectivity of our initial inhibitors over cathepsins S and K was imparted to some extent by a small P~2~ group, whereas cathepsins S and K prefer larger groups in this position. Despite cathepsin B being the least like Der p 1 when judged by amino acid sequence, optimization of selectivity over cathepsin B requires more chemical design effort to exploit the greater openness of the S~3~ pocket in Der p 1 which results from substitution by T^74^ in place of the bulkier Y^75^ in cathepsin B. The appreciation of these differences provided encouragement that novel inhibitors of the HDM allergens with appropriate selectivity profiles were achievable.

While not compromising the view that they are a single target for structure-based protease inhibitor design, detailed crystallographic investigations have revealed some minor differences between Der p 1 and Der f 1. Examples include the presence of a binding site for divalent cations which may be occupied in the case of Der p 1, but not Der f 1 ([@B76], [@B77]; [@B27]; [@B19]). Removal of divalent cations does not alter the proteolytic activity of Der p 1 (unpublished data), which distinguishes it from papain in which divalent cations increase catalytic activity ([@B19]). A further distinction between Der p 1 and other cysteine peptidases is its tendency to form oligomers in solution or in crystalline solid state ([@B27]; [@B19]), although Der f 1 lacks this behavior ([@B19]). Whether this oligomerization has biologic significance is unknown---the property is uncommon in cysteine peptidases generally, with cathepsin C being one of the few enzymes where it may be physiologically relevant. Although the IgE-binding epitopes of these allergens remain to be fully defined, structural analysis of a monoclonal antibody which binds both Der p 1 or Der f 1 shows that mutagenesis of the conserved allergen-binding site diminishes IgE binding, providing insight into a surface region which provides linear and/or conformational features for species cross-reactivity between Der p 1, Der f 1, and *E. maynei* 1 ([@B20]). This region is distant from the catalytic sites of these allergens, suggesting that IgE-bound allergens are catalytically active, creating the potential for the exercise of multiple bioactivities when interacting with sentinels such as mast cells and basophils. A further feature of this site is its poor conservation in Blo t 1, consistent with the low cross-reactivity of *Blomia* and *Dermatophagoides* allergens in allergic sera ([@B20]).

Allergy Initiators: Biologic Effects of Group 1 HDM Allergens {#s6}
=============================================================

For any protein to merit interest as a drug design target, a minimum requirement is that plausible evidence must exist to validate its association with a disease-related pathway. For group 1 HDM allergens, a clear association of the allergen with disease through precedented (i.e., IgE-dependent) mechanisms is historical reality, and persuasive contemporary evidence now links proteolytic activity to mechanisms considered core to the pathogenesis of allergy. These are summarized in [Table 2](#T2){ref-type="table"} and examined in depth in the subsequent sections. For these reasons, the group 1 HDM allergens may be considered "initiator" allergens, a highly exclusive cadre whose actions underpin and facilitate progressive polysensitization to allergens from unrelated sources (although the number of people exhibiting monosensitization is also significant). It is clear from [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} that the HDM allergen repertoire contains three serine proteases which replicate some of the effects of the group 1 cysteine proteases. In the airways, the nature of this redundancy underscores the selection of group 1 HDM allergens as the favored target, because the latter enable the redundancy of the serine peptidases through their ability to inactivate airway serpins while evading antiprotease defenses themselves. This provides a basis to anticipate that inhibition of a group 1 allergen will boost the defense against serine peptidase allergens by serpins. As discussed later, the correct proposal of protease target is endorsed by encouraging data for group 1 inhibitors in a variety of mechanistic models.

###### 

Allergy-related biologic actions and effects evoked by HDM protease allergens

  Sphere of Action                                                         Action or Effect                                                                                        Allergen or Extract                                                                                  References
  ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Mucosal defense                                                          Cleavage of tight junctions/reduced epithelial barrier function/allergen delivery                       HDM fecal pellet extract, Der p 1, Der f 1, Der p 3, Der p 6                                         [@B51], [@B52], [@B133], [@B129], [@B127], [@B128], [@B84]; ADI program---data on file
                                                                           Disruption of epithelial adherens junctions                                                             Der p 1 (directly and indirectly via ADAM 10)                                                        [@B129]; ADI program---data on file
                                                                           Inactivation of airway antiproteases                                                                    Der p 1                                                                                              [@B61], [@B12]
                                                                           Epithelial-mesenchymal transition                                                                       HDM extract                                                                                          [@B49], [@B33]
                                                                           Inactivation of surfactant proteins                                                                     Der p 1, Der f 1                                                                                     [@B23]
                                                                           IgE-independent mast cell stimulation                                                                   Der p 1, HDM extract                                                                                 [@B69]
                                                                           Activation of NLRP3 inflammasome and apoptosis                                                          HDM extract, Der p 1                                                                                 [@B133], [@B7], [@B33]
  Cell signaling                                                           Prothrombinase activity                                                                                 HDM fecal pellet extract, Der p 1                                                                    [@B136], [@B137]
                                                                           PAR-1 and PAR-4 activation                                                                              Der p 1 (indirectly as prothrombinase)                                                               [@B136]; ADI program---data on file
                                                                           PAR-2 activation                                                                                        HDM fecal pellet extract, Der p 1, Der p 3, Der p 9                                                  [@B114], [@B6], [@B59], [@B62], [@B17], [@B25], [@B94], [@B136], [@B99]
                                                                           PAR-1 inactivation                                                                                      Der p 1                                                                                              [@B6]
                                                                           PAR-2 inactivation                                                                                      Der p 1                                                                                              [@B1], [@B62]
                                                                           PAR-1 and PAR-2 upregulated expression                                                                  Der p 1                                                                                              [@B108]
                                                                           Mas-related G-protein--coupled receptor activation                                                      Der p 1                                                                                              [@B99]
                                                                           EGFR activation in epithelial cells                                                                     Der p 1 (indirectly as prothrombinase)                                                               [@B136], [@B137]; ADI program---data on file
                                                                           Pannexon gating in epithelial cells                                                                     Der p 1 (indirectly as prothrombinase)                                                               [@B136], [@B137]; ADI program---data on file
                                                                           ATP release from epithelial cells                                                                       Der p 1 (indirectly as prothrombinase)                                                               [@B136], [@B137]; ADI program---data on file
                                                                           ADAM 17 activation in epithelial cells                                                                  Der p 1 (indirectly as prothrombinase)                                                               [@B16], [@B137]
                                                                           ADAM 10 activation in epithelial cells                                                                  Der p 1 (indirectly as prothrombinase)                                                               [@B16]; ADI program---data on file
                                                                           ADAM 8 activation in epithelial cells                                                                   Der p 1 (indirectly as prothrombinase)                                                               ADI program---data on file
                                                                           Cleavage of low-affinity IgE receptor (CD23)                                                            Der p 1 (directly and indirectly via ADAM 10)                                                        [@B106]; ADI program---data on file
                                                                           Activation of endogenous interstitial prothrombinase                                                    HDM extract (due to Der p 1)                                                                         [@B136]; ADI program---data on file
  Regulation of gene expression and exploitation of antioxidant deficits   ROS generation                                                                                          Intracellular ROS by HDM fecal pellet extract, Der p 1 in epithelial cells, Der f 1 in neutrophils   [@B35], [@B136], [@B137], [@B16]
  Immune activation and allergic polarization                              Breaking of immune tolerance                                                                            HDM extract, Der p 1                                                                                 [@B39], [@B40], [@B38]; ADI program---data on file
                                                                           Suppression of indoleamine 2,3-dioxygenase                                                              Der p 1                                                                                              [@B70]
                                                                           TLR4 ligation                                                                                           HDM extract, Der p 1 (indirectly as prothrombinase)                                                  [@B137]; ADI program---data on file
                                                                           Bioactivating cleavage of IL-33                                                                         Der p 1                                                                                              [@B14]
                                                                           Cytokine/chemokine expression and release (e.g., IL-33, TSLP, CCL2, CCL20, GM-CSF, IL-8, IL-13, etc.)   HDM extract, Der p 1, Der p 3, Der p 6, Der p 9                                                      [@B64], [@B90], [@B1], [@B63], [@B87], [@B62], [@B108], [@B4]; ADI program---data on file
                                                                           Cleavage of IL-2R (CD25)                                                                                Der p 1                                                                                              Schulz et al. (1998)
  Antigen-presenting cell recruitment and activation                       Dendritic antigen-presenting cell recruitment                                                           HDM extract, Der p 1                                                                                 [@B90], [@B102]; ADI Program---data on file
                                                                           Cleavage of DC-SIGN/DC-SIGNR                                                                            Der p 1                                                                                              [@B36]
  Interaction with viral RNA sensors                                       Transductional convergence with signaling from TLR3 and TLR7                                            HDM fecal pellet extract, Der p 1                                                                    [@B137]; ADI Program---data on file
  Effector mechanisms                                                      Leukocyte recruitment                                                                                   Der p 1, HDM extract                                                                                 [@B102], [@B86]; ADI program---data on file
                                                                           Kinin generation from low- and high-molecular-weight kininogens                                         Der f 3                                                                                              [@B116], [@B73], [@B72]
                                                                           Decreased cysteine protease inhibitory activity of kininogens                                           Der f 3                                                                                              [@B72]
                                                                           Anaphylatoxin generation                                                                                Der f 3                                                                                              [@B74]
                                                                           IgE-independent "pseudoallergic" bronchoconstriction                                                    Der p 1, HDM extract                                                                                 ADI program---data on file

DC-SIGNR, DC-SIGN receptor; EGFR, epidermal growth factor receptor; GM-CSF, granulocyte macrophage-colony stimulating factor.

 {#s7}

### Mucosal Defenses. {#s8}

Antigen-presenting cell networks of the lung (dendritic cells) and skin (Langerhans cells) are the sentinels which link innate and adaptive immune responses. These cells process signals from activated innate immune mechanisms, such as pattern-recognition receptors, and present antigen to T cells after their migration to lymph nodes. To minimize nuisance triggering by low-grade external threats or the host microbiome, antigen-presenting cells and pattern-recognition receptors exhibit a polarized distribution, with many of these receptors and cells protected by the epithelium. Epithelial cells, airway macrophages, and components of airway surface liquid are thus the front line of defense against allergens and other immunologic threats. In understanding the initiation of sensitization and the processes which ensure its persistence, a key question is how allergens contact antigen-presenting cell networks, either by crossing mucosal barriers themselves or by promoting the ability of antigen-presenting cells to sample from the external environment. Of all allergens, the proteases of HDM have been the most studied in this regard, notably in the airways whose simple epithelial structure, intercellular junctions, and permeability characteristics are well characterized. The more complex stratified epithelium of skin is less extensively studied in the context of allergen disposition, reflecting that the role of tight junctions (TJs) in regulating skin permeability was itself unclear until the beginning of this millennium.

The first detailed studies of HDM allergen interactions with epithelial cells used a combination of functional, biochemical, and two-photon molecular excitation microscopy with three-dimensional isosurface image reconstruction, although earlier examination of permeability effects had been reported several years earlier ([@B51], [@B52]; [@B129], [@B127], [@B128]). These investigations revealed that TJs in human airway epithelial cells exposed to HDM fecal pellets were cleaved under conditions that mimic daily exposure to the allergens ([Fig. 1](#F1){ref-type="fig"}), resulting in a nonspecific increase in paracellular permeability (i.e., the barrier becomes leaky to all allergens, regardless of origin, and may also facilitate dendritic, and other, cell migration). The underlying mechanism is a proteolytic attack by cysteine peptidase and serine peptidase HDM allergens on the extracellular domains of occludin and claudins ([@B129], [@B128]), transmembrane proteins which form the contiguous intercellular contacts at the apical pole of the cells and which are adhesive components of the supramolecular TJ complex. In turn, this extracellular proteolytic cleavage initiates intracellular processing of the TJ plaque protein, ZO-1. Whereas epithelial permeability control is likely to depend on the ensemble function of various TJ adhesion proteins, lung-specific claudin-18 is known to be important in the type 2 T-helper cell (Th2)--high asthma phenotype. In common with claudins of TJs in other tissues, claudin-18 is downregulated by IL-13 (whose release is augmented by peptidase allergens), and its loss impairs epithelial permeability control in model systems in vitro and in vivo ([@B115]). Thus, the ability of protease allergens to cleave TJs directly and to affect their function through cytokine expression provides a powerful mechanism to compromise epithelial defense. As described later, this is accompanied by protease-driven inflammatory events in which the intracellular generation of reactive signaling molecules plays a key role and which provides a link to the activation of Toll-like receptor 4 ([Fig. 1](#F1){ref-type="fig"}; [Table 2](#T2){ref-type="table"}).

![(A and B) Three-dimensional isosurface reconstruction of fluorescent antibody labeling of TJs (green) and desmosomes (red) in human airway epithelial cells. Normal cells are shown in (A); note the contiguous rings of TJs compared with the punctate staining of desmosomes. (B) Two hours after exposure to HDM allergen, note the loss of TJ staining, whereas desmosomes remain intact. (C and D) Human airway epithelial cells labeled with NucBlue and MitoSOX red (Life Technolgies, Renfrewshire, UK) in the absence of HDM allergen stimulation (C) or following exposure to mixed HDM allergens showing generation of intracellular ROS (D). (E) Progress curves showing formation of rhodamine in calu-3 cells loaded with dihydrorhodamine under control conditions (circles), after stimulation by mixed HDM allergens (triangles), or after allergen stimulation in the presence of an allergen delivery inhibitor (squares). (F) Initial rates of ROS formation derived from rhodamine formation in (E). (G) Silencing of TLR4 expression by siRNA attenuates intracellular ROS generation evoked by mixed HDM allergens in calu-3 cells. Data for transfected control cells (con) and nontransfected cells are shown for completeness. (H) Concentration-dependent inhibition of intracellular ROS formation by TAK-242 (an inhibitor of the association between TLR4 and the signaling adapter proteins TIRAP and TRAM) in calu-3 cells stimulated by mixed HDM allergens (circles) or Der p 1 (triangles). The bar chart depicts the rate of ROS formation (dihydrorhodamine oxidation) in unstimulated cells or in the presence of allergen activation. (I) Gene silencing of the production of the *α*-chain of fibrinogen inhibits ROS generation by mixed HDM allergens. For (E--H), all data are shown as the mean ± S.E. with *n* = 4--8. \**P* \< 0.001 vs. vehicle (veh); \*\**P* \< 0.001 vs. HDM; ^†^*P* \< 0.05 vs. nontransfected HDM control. HDM 0.1, 1 refer to a natural mixture of allergens containing 0.1 or 1 *µ*g ml^−1^, respectively. Further methodological details concerning the studies in (C--I) are available ([@B136], [@B137]), and these form the basis of previously unpublished or recomposited data shown here. RFU, relative fluorescence units.](mol.118.112730f1){#F1}

An analogous mechanism operates in skin where HDM protease allergens cause the epidermis to become leaky and then impede its restitution ([@B84]; [@B59]), while at the same time promoting cytokine and chemokine production, which is similar to the response in airways ([@B5]; [@B87]; [@B88]; [@B4]) ([Table 2](#T2){ref-type="table"}). The cleavage of TJs in keratinocytes affords the opportunity for Langerhans cells, which express TJ proteins themselves, to form new TJs with keratinocytes, enabling an upregulation of antigen sampling while, at least initially, retaining barrier integrity ([@B65]). Similar behavior occurs in allergic rhinitis where, unlike nonrhinitic controls, the dendrites of antigen-presenting cells penetrate beyond the apical surface of the nasal epithelium ([@B118]). However, chronic allergen exposure or other predisposing factors for epithelial leakiness, such as loss of function mutations in filaggrin or dysregulation of lipid composition in the stratum corneum of the skin, result in augmented immunologic responsiveness to allergens. Indeed, emerging evidence suggests that clinically unaffected skin barrier properties in atopic dermatitis are compromised, as decreased levels of claudins-1, -4, and -23 have been found in nonlesional skin, and an inverse relationship between claudin-1 and Th2-polarized responses has been observed ([@B24]; [@B10]).

Although the allergen repertoire of HDMs consist of several proteases, the particular importance of group 1 allergens, such as Der p 1, is indicated by the prevention of transepithelial delivery of allergen when TJ cleavage is blocked ([@B129]), and when the proteolytic activity of Der p 1 is inhibited, intranasally administered HDM allergens no longer evoke allergic sensitization in mice. Thus, the serine protease HDM allergens, despite cleaving TJs ([@B128]), have a subordinate role in driving allergic sensitization.

In addition to the physical defenses, epithelial surfaces offer protection against pathogens through biochemical mechanisms ([Table 2](#T2){ref-type="table"}). Antiproteases are one facet of biochemical defense relevant to interactions with protease allergens, especially in the airways where epithelial surface liquid is rich in *α*~1~-antitrypsin capable of inhibiting the effects of serine protease allergens. However, Der p 1 inactivates this serpin and is itself resistant to most mammalian antipeptidases except *α*~2~-macroglobulin, whose molecular weight restricts its presentation at the airway surface ([@B61]; [@B12]). Other targets of Der p 1 in airway surface liquid are surfactant proteins --A and --D, members of the collectin family of C-type lectin receptors. The function of these proteins in innate immunity is opsonization of pathogens for phagocytosis, but as their names imply, they also control surfactant production and may offer some protection against allergy development ([@B23]).

### Cell Signaling and HDM Protease Allergens. {#s9}

In addition to the events that promote the physical interaction of allergens with antigen-presenting cells, HDM protease allergens initiate a sophisticated series of events within the sphere of innate immunity. Cells that are in the front line of interactions with allergens (viz. macrophages, epithelial cells, keratinocytes, dendritic cells, and mast cells) express an extensive palette of innate immune receptors which are central to the events that initiate and perpetuate allergy. Cytokine production is one of their outputs with a prominent role in progressively driving disease symptoms and exacerbations. The main goal of clinical management in allergy is prevention of exacerbations, so interruption of this chain of events at key checkpoints should offer significant patient benefit.

### Group 1 HDM Allergens Are Prothrombinases. {#s10}

Unexpectedly, one of the proteolytic features of Der p 1 is its ability to behave as a prothrombinase, forming thrombin from prothrombin independently from classic coagulation pathways ([@B136]) ([Table 2](#T2){ref-type="table"}). In airway epithelial cells, this effect of Der p 1 is augmented by the subsequent activation of an endogenous prothrombinase, which plays a major role in controlling the generation of reactive signaling molecules ([@B137]). These recent discoveries cast an exciting new perspective on how group 1 HDM allergens upregulate cytokine expression through the operation of a signaling cycle which interlinks components having a pleiotropic role in allergy specifically, or innate immunity generally ([Fig. 2A](#F2){ref-type="fig"}). At the time of writing, the exact relationships between many key events in this cycle remain to be defined, but what is known suggests that group 1 HDM allergens are, by means of their proteolytic activity, the ignition keys of fundamental innate responses. Consequently, novel molecular entities which inhibit the proteolytic activity of group 1 HDM allergens affect a broad spectrum of events relevant to allergy initiation and maintenance ([@B137]).

![(A) The prothrombinase activity of Group 1 HDM allergens stimulates intracellular ROS formation in airway epithelial cells through an ATP and ADAM 10--dependent regenerating cycle initiated by the canonical cleavage of PAR-1 and PAR-4. The formation of endogenous ligands for TLR4 plays a key permissive role in this process because silencing of receptor expression or prevention of TLR4 interactions with intracellular adapter proteins blunts ROS formation. This signaling cycle receives convergent stimulatory inputs from viral RNA sensors (TLR3/MDA-5/RIG-I/TLR7) upstream from the gating of pannexons by myosin motors. ROS provide transcriptional regulation of gene expression through multiple mechanisms. Direct formation of thrombin by group 1 HDM allergens (prothrombinases) appears to be functionally compartmentalized from the ADAM 10--dependent generation of prothrombin because PAR-1, PAR-4, and pannexin-1 are required for the former. Although the underlying reasons for this dichotomy are not established, it may reflect poor accessibility of apically generated ligands to TLR4 in a polarized epithelium. The figure was revised and updated with added mechanistic details from the scheme originally published by [@B137]. (B) Gene silencing production of the *α*-chain of fibrinogen in calu-3 airway epithelial cells inhibits ROS generation activated by ligation of P~2~X~7~ (2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate, BzATP) or P~2~Y~2~ (uridine-5′-tetraphosphate δ-phenyl ester tetrasodium salt, MRS2768) receptors. \**P* \< 0.001 vs. vehicle (veh) controls; \*\**P* \< 0.001 vs. stimulated cells (nontransfected and transfection control, con). (C) Gene silencing of ADAM 10 or ADAM 8 attenuates ROS production by calu-3 cells stimulated by mixed HDM allergens containing Der p 1 at 1 *µ*g ml^−1^. \**P* \< 0.001 vs. veh controls; ^†^*P* \< 0.001 vs. stimulated cells; ^‡^*P* \< 0.001 vs. veh controls. Data in (B and C) are shown as the mean ± S.E. (*n* = 8). The new data shown in (B and C) used methods which have been published elsewhere ([@B136], [@B137]). EGFR, epidermal growth factor receptor; RFU, relative fluorescence units.](mol.118.112730f2){#F2}

Through its interstitial prothrombinase activity, Der p 1 enables the canonical activation of protease-activated receptor-1 (PAR-1) and PAR-4 by thrombin in a manner consistent with the formation of a ternary complex of thrombin with receptor hetero-oligomers ([@B16]) ([Table 2](#T2){ref-type="table"}). This is the beginning of a regenerative cycle ([Fig. 2A](#F2){ref-type="fig"}) from which key outputs are reactive oxygen and nitrogen species. Although natural mixtures of HDM allergens contain both serine and cysteine proteases, with the former as candidates for the activation of PAR-2, potent and selective inhibitors of Der p 1 attenuate the production of virtually all of the reactive species, suggesting that it is the major component within the repertoire of the allergen mixture responsible for their generation. That PAR-2 cleavage makes only a minor contribution is indicated by the small effects of either its pharmacologic antagonism or silencing by small interfering RNA (siRNA). Probe studies with a DNA-binding triphenylphosphonium analog of dihydroethidium indicate that at least some of this generation occurs in mitochondria through a two-electron reduction of oxygen, and this establishes the basis for a mechanism for the upregulation of cytokine production through well characterized mechanisms, notably those dependent on the transcription factor nuclear factor *κ*B ([@B136]; [@B16]). Reactive oxidant species activate transcription factors and induce histone modifications favoring the induction of proallergic cytokines, whereas through direct transformation of proteins, they activate mitogen-activated protein kinase and the signal transducer and activation of transcription pathways which are implicated in allergy and asthma ([@B22]; [@B124]). Other studies have provided direct evidence of DNA damage resulting from HDM exposure in mice and human lung cells, mirroring underlying events observed in asthma ([@B15]).

### Group 1 HDM Allergens, Pannexon Gating, and ATP Release. {#s11}

Downstream from the Der p 1--dependent activation of PAR-1/4 lies the opening of pannexons which, inter alia, result in the extracellular release of ATP ([Fig. 2A](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). These pannexons are assembled from pannexin-1, and the release of ATP operates as an innate alarm mechanism by signaling through P~2~X~7~, P~2~Y~2~, and, to a lesser extent, P~2~Y~4~ receptors, leading to the activation of A disintegrin and metalloprotease 10 (ADAM 10) and eventuating in the production of reactive oxygen species (ROS). The recruitment of ADAM 10 into this cycle is notable in that its other actions---namely, promoting IgE synthesis through its cluster of differentiation 23 (CD23) sheddase activity on B-lymphocytes (also a direct effect of Der p 1), and recruiting dendritic cells, eosinophils, neutrophils, and T cells through C-C chemokine ligand 20 (CCL20), CCL2, CCL5, C-X-C motif chemokine ligand 8 (CXCL8), and CXCL16 release---signify a pleiotropic role in allergy, whereas its sheddase action on E-cadherin of adherens junctions suggests an augmenting role in dysregulation of epithelial barrier permeability ([@B106]; [@B41]; [@B130]; [@B57]; [@B75]; [@B95]) and the promotion of epithelial-mesenchymal transition (EMT). However, in airway epithelial cells responding to HDM allergens, it also appears that ADAM 10 initiates further conversion of prothrombin to thrombin---indirectly, directly, or both---but via events that are significantly downstream from the prothrombinase activity of Der p 1. The ligand shedding activity of ADAM 10 is Ca^2+^-dependent ([@B83]; [@B100]), so an association with the opening of pannexons, which are permeable to both mono- and divalent cations, may be critical in its activation. Recent studies from our laboratory indicate that ADAM 8 may provide some support for ADAM 10 in this cycle, suggesting an analogous relationship to that involved in CD23 shedding, where ADAM 10 is the constitutive sheddase whose action can be duplicated, if necessary, by ADAM 8. The endogenous production of thrombin activated by ADAM 10 and ADAM 8 is required for the generation of reactive signaling species, which led us to consider what the further downstream consequences of these reactions might be.

### Group 1 HDM Allergens and Toll-Like Receptor 4 Ligation. {#s12}

Revealingly, we found that effective blockade of ROS formation occurred by siRNA silencing of Toll-like receptor 4 (TLR4) or pharmacologic inhibition of its interaction with the adapter proteins TIRAP and TRAM by ethyl-(6*R*)-6-(*N*-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate (TAK-242) ([@B137]). Attenuation of responses by a Der p 1 inhibitor shows that this activation of TLR4 requires Der p 1 and is independent of ligation by bacterial lipopolysaccharides (LPS), the archetypal agonists of this receptor ([@B137]). Although LPS is present in house dust and HDM allergen mixtures, LPS is only weakly effective in triggering ROS production, at least in healthy airways, because of a deficiency in the myeloid differentiation protein-2 (MD-2) co-receptor and the polarized basolateral distribution of TLR4, which protects it from nuisance triggering by exogenous signals. However, TLR4 is activated by a range of putative endogenous ligands which include fibrinogen and its cleavage products ([@B54]; [@B30]; [@B135]; [@B78]; [@B18]). Airway epithelial cells secrete fibrinogen from their basolateral aspect in a vectorial, microtubule-dependent manner and are one of few extrahepatic sites where all three component chains of the protein are expressed ([@B43]). This leads to the possibility that fibrinogen cleavage products are the agencies by which Der p 1--dependent TLR4 activation is achieved, although ensemble participation of other TLR4 ligands should not be excluded. The involvement of fibrinogen is indicated by attenuation of responses in airway epithelial cells in which expression of the FGA gene, which encodes the *α*-chain of the protein, has been silenced by siRNA ([Fig. 2B](#F2){ref-type="fig"}). The Der p 1--dependent activation of TLR4 is, therefore, a consequence of the chain of signaling events initiated by its activation of PAR-1 and PAR-4, and the TLR4-dependent action of selective P~2~Y~2~R or P~2~X~7~R agonists suggests that the coupling of TLR4 ligation to ROS production occurs downstream from the gating of pannexons ([@B137]).

Discovery of a linkage between Der p 1 and TLR4 is of considerable interest because TLR4 expressed on airway epithelial cells is an indispensable requirement for the development of allergic sensitization to HDM allergens ([@B45]). Ligation of TLR4 leads to an activation of cells by IL-1*α* and the release of granulocyte macrophage colony-stimulating factor and IL-33 ([@B131]), the latter being a bioactivation target of the Der p 1 enzyme also ([@B14]) ([Table 2](#T2){ref-type="table"}). The importance of TLR4 and this triad of cytokines is demonstrated by depletion of the receptor or cytokine neutralization preventing allergic responses ([@B45]; [@B131]). Until the discovery of how Der p 1 leads to TLR4 activation, the mechanisms offered to account for the indispensability of TLR4 were: 1) the presence in PAR-2 of a potential Toll/interleukin-1 receptor domain which might bind to myeloid differentiation primary response 88 (MyD88) in the TLR4 signaling complex, which regulates early nuclear factor *κ*B--dependent gene transcription ([@B8]); and 2) the similarity between group 2 HDM allergens and MD-2, which functions as a co-receptor protein in the response to LPS ([@B29]; [@B121]). A structural feature linking the group 2 HDM allergens with MD-2 is the presence of a large hydrophobic pocket capable of binding lipophilic ligands such as LPS. The attraction of this MD-2 mimicry by group 2 HDM allergens is that it might provide a means to compensate for a relative deficiency of MD-2 in airway epithelial cells and offers a mechanistic connection to LPS which is implicated in allergy development under certain conditions. However, MD-2 mimicry suffers limitations as a central initiator mechanism, not least in failing to accommodate the cellular distribution of TLR4 in a healthy-airway epithelium. Unlike group 1 HDM allergens, those of group 2 neither initiate ROS production nor have a direct effect on epithelial barrier properties when protease contamination is rigorously excluded. Indeed, studies on the transepithelial disposition of Der p 2 show that significant permeation occurs only in the presence of proteolytically active group 1 allergens and can be prevented by a novel Der p 1 inhibitor of high potency. Moreover, inhibition of Der p 1 proteolytic activity prevents allergic sensitization in mice ([@B39], [@B40]; [@B138]; [@B102]), an effect which is hard to reconcile with the indispensability of TLR4 being solely reliant on MD-2 mimicry. Our data provide an alternate rationale where the decisive event is thrombin formation by the direct prothrombinase activity of group 1 HDM allergens which, in turn, facilitates the formation of endogenous TLR4 ligands in the airway epithelium through activation of an additional endogenous prothrombinase ([@B136], [@B137]). The identities of these endogenous TLR4 activators remain unclear, but gene silencing of any one of the three component chains of fibrinogen abrogates ROS production by Der p 1 in human airway epithelial cells, although other ligands appear to participate too ([Fig. 2B](#F2){ref-type="fig"} and our unpublished data). Significantly, selective inhibitors of Der p 1 provide effective inhibition of all these events ([@B137]). It is evident from the foregoing that the airway epithelium is the cellular host of a sophisticated signaling nexus which combines the physical delivery of allergen to antigen-presenting cells, and thereby T-lymphocytes, with the creation of a signaling environment which transduces the progression from innate to acquired immunity with an allergic polarization.

### Signaling Convergence Between Group 1 HDM Allergens and Viral RNA Sensors. {#s13}

A fascinating aspect of this HDM allergen--dependent route to TLR4 ligation and the production of reactive intermediates which regulate gene expression is that the signaling mechanisms converge with cellular responses initiated by ligation of the viral RNA sensors TLR3 and TLR7 ([Fig. 2A](#F2){ref-type="fig"}; [Table 2](#T2){ref-type="table"}) ([@B136], [@B137]). The point of convergence lies upstream from the myosin motor−dependent gating of pannexons and ATP release ([@B137]). In allergic asthma, disease exacerbations arise from interactions between allergens and respiratory viruses (principally rhinovirus, respiratory syncytial virus, and influenza), so the identification of a nexus linking these stimuli provides new insight into how these exacerbations are precipitated. Interestingly, given the regenerative cycle which underlies this production of ROS, activation of PAR-1 contributes to the pathogenicity of influenza A, and PAR-1 and TLR3 are both upregulated by infections caused by respiratory viruses ([@B42]; [@B3]).

### Thrombin and ATP: Innate Effector-Perpetuators in Allergy. {#s14}

It has been known for some time that concentrations of thrombin in airway surface liquid are elevated in asthma to levels which are capable of driving cell proliferation, and they are also raised following respiratory virus infection ([@B120]). Whereas some thrombin may result from tissue-repair mechanisms activated by inflammation, more recent data suggest that it also functions as an innate strategic initiator and an effector-perpetuator of allergy through its direct generation by inhaled Der p 1 ([@B136]). Similarly, ATP is present in elevated concentrations in bronchoalveolar lavage fluid in asthma ([@B81]), consistent with the allergen-dependent gating of pannexons. In addition to triggering ROS generation, it initiates the release of IL-33, which is pivotal in the orchestration of responses mediated by ILC2 cells and promotes a Th2 bias in dendritic cells ([@B56]; [@B81]). The actions of ATP extend downstream from these events and additionally activate mast cells, eosinophils, and cause dyspnea ([@B105]; [@B9]). In keeping with the foregoing, novel Der p 1 inhibitors which abrogate thrombin generation and pannexon-dependent ATP release also attenuate eosinophil recruitment, inhibit the release of IL-33 and TSLP, and impair acute allergic bronchoconstriction ([@B86] and our unpublished data). Their ability to reduce IL-33 production in the airways removes a critical component of innate immune signaling which directs the development and persistence of allergic sensitization and some of its key pathophysiologic features.

### Activation of PAR-2 and Mas-Related G-Protein--Coupled Receptor X1. {#s15}

The discovery of PARs naturally prompted speculation that they could be receptors for protease allergens, especially those, like the group 3 and group 6 HDM allergens, with substrate preferences similar to canonical activators of these receptors. That group 1 HDM allergens would interact with one or more of these receptors was assumed to occur through an example of biased agonism. The ability of HDM allergen extracts and purified allergens to stimulate cytokine (e.g., IL-6, IL-8, CCL11, granulocyte macrophage colony-stimulating factor) release from airway epithelial cells or keratinocytes in a manner which paralleled the effects of PAR agonist peptides reinforced this view, especially highlighting PAR-2 as an important molecular recognition system for protease allergens with a central mechanism in disease ([@B64]; [@B62]). However, subsequent investigations suggested that an association of PAR-2 with asthma and other allergic conditions is complex. Illustratively, in mouse models of HDM sensitization, it is dispensable ([@B6]; [@B1]; [@B94]), and in some disease models, PAR-2 activation dampens rather than escalates inflammation ([@B26]; [@B28]); in the case of group 1 HDM allergens, there are conflicting accounts of whether PAR-2 cleavage is an activation signal at all. Furthermore, the discovery that Der p 1 is a prothrombinase which initiates the PAR-1- and PAR-4--dependent ligation of TLR4 introduces a significant new dimension to how protease-mediated signaling promotes and maintains allergy.

An aspect of chronic asthma which may link Der p 1 and PAR-2 is airway remodeling and EMT, in which transforming growth factor-*β* is a key element ([@B44]). Group 1 HDM allergens activate latent transforming growth factor-*β* and promote EMT characterized by a PAR-2 and epidermal growth factor receptor--dependent reduction of E-cadherin expression by epithelial cells ([@B84]; [@B49],[@B50]; [@B33]), which in turn is a stimulus for the upregulation of CCL17 and TSLP ([@B48]). As described earlier, Der p 1 activates PAR-4, which itself is implicated as an initiator of EMT, and the ensuing cycle which leads to ROS formation involves ADAM 10, a key sheddase of E-cadherin ([@B2]; [@B57]; [@B16]).

Attention has also turned to the activation of other receptors in conjunction with PARs. Data have been obtained to show that Der p 1 activation of the orphan receptor Mas-related G-protein coupled receptor X1 (MRGPRX1) from the mas-related G-protein--coupled receptor family contributes to PAR-2--dependent cytokine release from cultured human airway epithelial cells ([@B99]), although the relevance to allergy remains untested. However, a possible link between Der p 1 and MRGPRs is intriguing because of their expression in sensory neurons and mast cells. The latter degranulate in response to the proteolytic action of Der p 1 through an uncharacterized mechanism independent from IgE cross-linkage ([@B69]). In the context of MRGPRs (and PARs) transducing the nociception of pain and itch, the ability of a protease to activate such physiologic responses is well established, not least through the use of spicules from pods of the cowhage plant (*Mucuna pruriens*), which contain the cysteine protease mucunain, as an experimental stimulus in human volunteers ([@B134]; [@B11]; [@B107]; [@B98]). Others will be aware of mucunain\'s efficacy at inducing a burning pain by prank exposure to "itching powder," a favorite product of novelty shops. One unexpected feature which became quickly evident in early studies with cowhage is that its ability to induce pruritis is heavily reliant on histamine release ([@B11]), suggesting that the concept of pseudoallergic, protease-dependent mast cell activation should be revisited in the context of contemporary receptor biology and innate immunity.

### Group 1 HDM Allergens and Deficits in Antioxidant Defense. {#s16}

One of the long-standing enigmas of allergy is why environmentally pervasive inhalant allergens evoke sensitization in only a subset of the exposed population. The generation of ROS by airway epithelial cells as an innate response to group 1 HDM allergens suggests a scheme to account for some of this difference in susceptibility. It is well established that a deficit in enzymatic and nonenzymatic antioxidant defenses is common in asthma ([@B104]; [@B22]). Some of these are genetically determined ([@B34]; [@B111]; [@B71]), whereas others may arise consequentially from the development of disease. These deficits are exacerbated by the pathogenetic upregulation of oxidant production, such as the induction of NADPH oxidase subunits by cytokines. HDM allergen extract increases the selective expression of DUOX-1 in human airway epithelial cells, and this is correlated with enhanced release of hydrogen peroxide and IL-33 ([@B55]). In asthma, allergen exposure increases DUOX-1 expression by the nasal epithelium, and neutrophil-derived ROS production by Der f 1 is greater than in controls without asthma ([@B35]). The enhancement of ROS production by certain allergens may itself be a further factor in promoting the allergenicity of other exogenous proteins through carbonyl adduction to form reactive aldehydes which can direct a Th2 proliferative bias in T-lymphocytes ([@B79]).

A key role for oxidant/antioxidant balance in shaping the development of allergy is suggested by compelling evidence from disease models. In mice, the cysteine protease papain promotes sensitization through mechanisms involving oxidative stress ([@B119]), and partial inhibition of protease activity blunts the capacity of HDM allergen extract to induce allergic inflammation ([@B123]). Correspondingly, mice deficient in the master antioxidant regulator nuclear factor (erythroid-derived 2)-like 2 (Nrf2), or which are unable to upregulate it, develop enhanced responses to ovalbumin or HDM allergens ([@B97]; [@B132]; [@B67]; [@B123]). Similarly, glutathione depletion exacerbates airway hyper-reactivity and inflammation ([@B82]). Consistent with this theme, an Nrf2 activator protected against IL-33 release and allergic responses ([@B122]), whereas overexpression of Nrf2 enhanced the expression of ZO-1, occludin, and E-cadherin in the airway epithelium ([@B21]).

### Antigen-Presenting Cell Recruitment. {#s17}

Accumulation of antigen-presenting cells at mucosal surfaces and their departure for interaction with T-lymphocytes is a strategic conduit linking innate and acquired immune responses to allergens. This is demonstrated by the observations that HDM allergen exposure recruits antigen-presenting cells to lung \[dendritic cells (DCs)\] and skin (Langerhans cells) through the agency of chemokine release (CCL2, CCL5, CCL20, and CXCL10) by epithelial cells ([@B90]), and that humanized SCID mice reconstituted with monocyte-derived DCs from patients with atopic asthma are predisposed to develop immune responses with a Th2 polarization ([@B46]). Transcriptomic analysis in HDM allergen--exposed airway epithelial cells or clinical airway specimens suggests that chemokines directed against antigen-presenting cells constitute part of an upregulated core gene repertoire ([@B125],[@B126]). Both CCL2 and CCL20 have been proposed as pivotal in the increased steady-state numbers of DCs in the bronchial mucosa of patients with asthma, with a notable increase in Der p 1--dependent CCL20 release in airway samples in atopic asthma ([@B90]). A role for CCL20 in response to HDM allergens is replicated in a mouse model where its release is TLR4-dependent ([@B45]). CCL20 is a ligand for C-C chemokine receptor 6 (CCR6), which is expressed on Langerhans cell--like precursors of conventional DCs that are associated with inflammatory events. In mice deficient in CCR6, allergic pulmonary responses are attenuated due to impaired migration of DCs ([@B68]). In contrast to HDM allergen responses, signaling via the CCL20/CCR6 axis does not occur with ovalbumin ([@B101]), which requires the collateral priming effects of the proteolytic activity of Der p 1 or another adjuvant for the development of robust IgE responses ([@B39], [@B40]; [@B31]; [@B138]). Release of CCL20 from human airway epithelial cells by HDM allergen extracts also occurs through a *β*-glucan--dependent route. This mechanism is protease- and TLR4-independent but involves Syk activation, suggesting that it might be mediated through the C-type lectin receptor, dectin-1 ([@B85]). Other work has suggested a role for *β*-glucan--dependent, TLR2-mediated signaling by HDM allergen extracts in the nasal mucosa ([@B103]). Similar to chitins \[*β*-(1,4)-poly-*N*-acetyl-[d]{.smallcaps}-glucosamine polymers\] which also ligate dectin-1 ([@B66]), *β*-glucans are extraneous factors in HDM culture extracts and components, from multiple sources, of environmental house dust, so this activation of chemokine production by multiple mechanisms is anticipated as a multilayered reinforcement of allergic polarization. Although these observations suggest the importance of CCL20/CCR6 signaling in the allergic recruitment of DCs, the pattern of chemokine and receptor activation seems likely to be more complex given that the high phenotypic plasticity of antigen-presenting cells provides them with a versatile repertoire of delegated effector roles. For this reason, selective intervention at targets within this particular checkpoint in the initiation and maintenance of allergy may be of variable benefit compared with other options. Illustrating the difficulty in validating CCL20/CCR6 as a discrete, primary target pairing, CCL2, CCL5, and CXCL10 chiefly act via ligation of CCR1, CCR2, CCR5, and CXCR3 found on DCs of monocyte derivation, and of these combinations, the interaction of CCL2-CCL2R is particularly interesting in allergy development because CCR2^+^Ly6c^hi^ monocytes are precursors of inflammatory CD11b^+^ DCs found in allergy ([@B101]; [@B45]).

Although antigen-presenting cell recruitment and activation may be driven primarily through signaling events triggered by HDM allergens in the airway epithelium, the allergens must also have direct interactions with antigen-presenting cells, and these have been the subject of some scrutiny in the context of protease-dependent activation and programming of Th2 polarization. One approach has been to use in silico prospecting for potential substrates of Der p 1 among the cell surface proteins found on dendritic cells, resulting in identification of C-type lectin receptor dendritic cell--specific intercellular adhesion molecule 3--grabbing nonintegrin (DC-SIGN) and its homolog DC-SIGN receptor as potential substrates of Der p 1 ([Table 2](#T2){ref-type="table"}). In support of this, recombinant DC-SIGN and DC-SIGN receptor are cleaved by Der p 1 in vitro ([@B36]). DC-SIGN expression is reduced in DCs exposed to Der p 1, although it is hard to ascertain how much of this disappearance is due to proteolysis or to protease-independent endocytosis ([@B63]; [@B36]).

The challenge of devising a successful antigen presentation checkpoint intervention is further demonstrated by another potential target of Der p 1 in DCs ([Table 2](#T2){ref-type="table"}). Der p 1 causes a downregulation of indoleamine 2,3-dioxygenase in HDM-sensitive individuals ([@B70]). Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine and causes immunosuppression through a combination of tryptophan depletion (which activates a sequence of events through induction of general control nonrepressed 2 kinase) and the direct cellular effects of kynurenine and other tryptophan metabolites ([@B60]). Consequently, downregulation of the enzyme by Der p 1 is a potentially interesting mechanism leading to the breaking of immune tolerance and the development and maintenance of sensitization. Indoleamine 2,3-dioxygenase activity is particularly important in antigen-presenting cells, although there is notable heterogeneity in its significance in different DC subsets, especially between conventional DCs and plasmacytoid DCs ([@B47]). The success of attempts to induce tolerance to an allergen by manipulation of indoleamine 2,3-dioxygenase activity may, therefore, depend on which subset(s) of DCs is most relevant. It should also be noted that chronically stimulating indoleamine 2,3-dioxygenase activity may not be generally beneficial because of the inherent risks associated with a concomitant attenuation of routine immune surveillance for pathogens and tumors ([@B80]; [@B47]). For these and other reasons, we preferred a different approach focused on the allergen rather than innate host checkpoints.

Allergen Delivery Inhibitors {#s18}
============================

The strong causative association of serodominant group 1 HDM allergens with major allergic diseases makes them a compelling target in the search for unprecedented interventions intended to modify the basic immunologic events that are responsible for the development of disease. As outlined in the earlier sections, and summarized by the actions listed in [Table 2](#T2){ref-type="table"}, understanding how their proteolytic activity drives these sentinel events provides encouragement that inhibitors of this proteolytic activity offer the prospect of disease modification. The chemical design challenge associated with this unprecedented mechanism was significant, and the identification of developable candidates necessitated the rigorous pursuit of a clear vision of the required attributes, some of which would be deemed an unusual focus in most early-stage discovery research. Given the similarity of group 1 HDM allergens as proteases, this enabled us to use Der p 1 as the archetypal template for inhibitor design. We call this new class of drugs "allergen delivery inhibitors" to reflect that they interfere with the ability of HDM allergens to engage with antigen-presenting cells. As will now be evident, this process of "delivery" is a combination of biophysical events in intercellular junctions and the creation of a complex molecular signaling pathway which leads from innate immunity to the acquisition and persistence of allergic sensitization.

Our approach to Der p 1 inhibitor design was informed by the fact that the targets are inhalant allergens, and preventing their effects at the site of initial impaction in the lungs would be advantageous. With a nonhuman inhaled target, the interaction with an inhibitor has no requirement for cell permeation, which, in combination with properties designed to minimize systemic exposure, means a significant opportunity to mitigate safety risks in chronic therapy. There are several device options for the delivery of drugs by inhalation, viz. nebulizer, metered dose inhaler, and dry powder inhaler (DPI). We elected to pursue compounds that would be compatible with DPI delivery, with the expectation that this would bring confidence for usage in other devices. Delivery by DPI imposes a burden on chemical design and pharmaceutics because it demands nonhygroscopic, stable, crystalline compounds which can produce particles of consistent size that will distribute uniformly to the site of action in the lung, in addition to embodying the pharmacologic profile for target selectivity, potency, safety, and duration of action.

Opening explorations of Der p 1 inhibitor design were based around the introduction of inhibitory warheads into a modified peptide substrate sequence based on the scaffold peptide VAJS. Contrary to the development of compounds for oral delivery, it is usually advantageous for inhaled asthma drugs to have poor oral bioavailability to minimize systemic exposure and thus achieve a good safety profile. Therefore, compounds which violate Lipinski "rules" provide interesting freedoms for inhaled drug design which would not usually be tolerated in other settings. A peptide template, with a high proportion of hydrogen bond donors and acceptors in a flexible scaffold, was therefore considered a useful departure point for such an application. An exemplar derived from this scaffold is aldehyde **1** ([Fig. 3](#F3){ref-type="fig"}), but despite encouraging potency, it was compromised by expectations of instability and nonspecific reactivity. Surprisingly, some warheads effective in the design of cysteine peptidase inhibitors directed at other targets were found to be poor inhibitors of Der p 1, such as vinylogous esters and sulfones elaborated from the scaffold of **1**. Initial progress in the search for potent Der p 1 inhibitors was made with the identification of a series of acyloxymethyl ketones exemplified by **2**, **3**, and **4** ([Fig. 3](#F3){ref-type="fig"}). Docking of **3** in Der p 1.0105 (Protein DataBank: A2S8) suggested that the norleucine side chain makes hydrophobic interactions with the P~1~ pocket while the carbonyl initially forms a reversible covalent bond with C^114^, and the NH a hydrogen bond with Y^249^ ([@B86]). Consistent with the mechanism of inhibition for acyloxymethyl ketones, C^114^ subsequently migrates to displace the acyl group, forming an irreversible covalent bond with the inhibitor. The amino and carbonyl groups of alanine hydrogen bond with D^154^, and the preference for compact groups at P~2~ arises because of I^156^. The side chain of valine makes a hydrophobic interaction with the P~3~ pocket, and the benzoyl capping group forms hydrophobic *π*-stacking associations with tyrosine residues. Although docking analysis provided useful information to guide subsequent chemical design, the acyloxymethyl ketones, per se, lack developability, primarily through concerns about their irreversible inhibition of the target. Therefore, the challenge was to identify functional groups which would enable the creation of compounds whose target inhibition was reversible while maintaining the benefits of slow off-rate. To this end, we investigated a series of inhibitors which were capable of forming a reversible covalent bond with C^114^. An advance toward this goal was a series of amino ketones which demonstrated the achievability of incorporating a reversible inhibitor motif into a scaffold, which offered good prospects for optimization. However, despite initially encouraging progress, it proved impossible to increase potency beyond that of compound **5** ([Fig. 4](#F4){ref-type="fig"}). This activity was deemed insufficient when rated against a compound developability profile whose potency requirements had been defined from empirical estimates of target exposure in humans and the need to be mindful of device dosage practicalities ([@B86]).

![(A) Inhibitors of Der p 1 identified in early discovery research. Activity for the reversible inhibitor aldehyde **1** is expressed as the inhibition constant, whereas data for the acyloxymethyl ketones with irreversible action are expressed as second-order inhibitor rate constants. Measurements were performed as described by [@B86] and the online supporting information, <https://pubs.acs.org/doi/suppl/10.1021/jm501102h> and <https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf>, using (3S,6S,9S,12S,15S,18S)-1-(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-12-(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazaicosan-20-oic acid as substrate. (B and C) Docking of compound **3** in the substrate-binding groove of Der p 1.0105 shown, respectively, as surface representation and simplified stick view revealing hydrogen bonding interactions with Derp 1. (D) General mechanism for irreversible inhibition of Der p 1 using acyloxymethyl ketone **3** as exemplar.](mol.118.112730f3){#F3}

![(A) Transition from irreversible to reversible binding mode inhibitors of Der p 1 by modification of the cysteine binding motif and identification of pyruvamide **7**. Inhibitor characteristics were determined as disclosed by [@B86] and the online supporting information, <https://pubs.acs.org/doi/suppl/10.1021/jm501102h> and <https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf>, using (3S,6S,9S,12S,15S,18S)-1-(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-12-(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazaicosan-20-oic acid as substrate. (B) General mechanism for reversible inhibition of Der p 1 using amino ketone **5** as exemplar.](mol.118.112730f4){#F4}

Reassurance that an uplift in potency could be achieved in a reversible inhibitor was provided by **6** ([Fig. 4](#F4){ref-type="fig"}), albeit using a functionality of limited developability. A pursuit of alternative groups led to the identification of a series of pyruvamides, such as **7** ([Fig. 4](#F4){ref-type="fig"}), which became the focus for detailed exploration ([@B86]). The inhibitory potency of **7** against the Der p 1 target is compatible with the declared profile for development, but it is not optimized with respect to properties which influence the persistence at the site of action or its selectivity over obvious off-target nuisances. As a design tool for optimization, a computational model was created based on the structure of Der p 1.0105 and on the structures of peptidic inhibitors bound to cathepsin K. Compound **7** was built and energy-minimized in the substrate-binding groove of Der p 1 with the electrophilic carbonyl of the pyruvamide moiety orientated to interact with C^34^ and the peptide backbone aligned to follow a trajectory similar to that of the other peptidic inhibitors. As shown in [Fig. 5](#F5){ref-type="fig"}, this revealed interactions between the amide carbonyl of the pyruvamide and the backbone NH of C^114^, the NH of the P~1~ subunit, and the carbonyl of Y^249^ and the formation of a donor:acceptor pair with the backbone carbonyl and NH of D^154^. This tool enabled the prioritization of chemical design decisions which were rigorously explored by iterative rounds of synthesis and screening, details of which are provided elsewhere ([@B86]). Counterscreening against Der f 1 provided confidence that compounds designed using Der p 1 as template were similarly active in other HDM species.

![Docking model of compound **7** bound to the active site of Der p 1.0105. Procedural details are presented by [@B86], <https://pubs.acs.org/doi/suppl/10.1021/jm501102h>.](mol.118.112730f5){#F5}

Pursuant to producing compounds which were efficacious against real-life allergen exposure and not just a single purified allergen, a range of in vivo studies were undertaken to establish confidence in developability ([@B86]). An example for compound **8** is shown in [Fig. 6](#F6){ref-type="fig"}. Eosinophils in bronchoalveolar lavage fluid were chosen as a readout in these studies because elevations in blood eosinophils and eosinophil recruitment to the airways are hallmark features of allergic asthma in many patients and correlate with disease severity. Importantly, these animals were sensitized and challenged with the complete palette of house dust mite allergens in a naturally derived mixture and not simply with the purified target allergen. As illustrated, a single inhaled dose of the compound produced a striking reduction in eosinophil recruitment after acute allergen challenge in an IgE-dependent model. This is an interesting result because our expectation is that ADIs will exhibit greatest benefits against underlying IgE-independent mechanisms which drive the acquisition and persistence of disease. Thus, even in a model where a strong IgE response existed and allergen challenge comprised a full palette of HDM allergens, targeting only the Der p 1 component produced a result suggesting useful efficacy ([@B86]).

![(A) Quaternary ammonium compound **8**. (B) Effect of a single aerosolized dose of **8** (18 nmol/kg) on the recruitment of eosinophils to the airways following aerosol challenge with mixed HDM allergens in sensitized brown Norway rats. The compound was administered 2 hours prior to HDM allergen by means of a Penn-Century aerosolizer (Penn-Century, Philadelphia, USA). Data are displayed as means ± S.E. in groups of 10 animals. \**P* \< 0.05 vs. vehicle (veh) challenge; \*\**P* \< 0.05 vs. HDM without test substance pretreatment; veh, vehicle. Full details of treatment protocols are provided by [@B86] and the online supporting information, <https://pubs.acs.org/doi/suppl/10.1021/jm501102h> and <https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf>. BAL, bronchoalveolar lavage.](mol.118.112730f6){#F6}

To further explore the chemical features necessary for a persistence of effect, we evaluated a subset of potent compounds which were stable in contact with airway cells. To neutralize additional variables created in IgE-dependent challenge models, we electively conducted investigations using animals which were HDM allergen--naïve because aerosol challenge with Der p 1 or HDM allergen mixtures results in eosinophil recruitment to the airways in the absence of HDM sensitization ([@B86]). The kinetics of this IgE-independent innate response are indistinguishable from sensitized animals, but the effect is smaller in magnitude. Compounds selected for these studies spanned a range of log *D*~7.4~ values and polar surface areas ([Fig. 7](#F7){ref-type="fig"}). Better efficacy was associated with lipophilicity, but good activity also existed in quaternary ammonium compounds (e.g., **8**, **14**) ([@B86]). As anticipated, the latter benefited from having low oral absorption, thus restricting systemic exposure in a manner which offers some advantages over alternate approaches where deliberately promoting the biotransformation of absorbed drugs can generate unexpected metabolic liabilities.

![(A) Relationship between inhibitor polar surface area and log D~7.4~ for a subset of compounds used for the examination of in vivo efficacy. Symbols depict ionization state at pH 7.4: neutral (purple circles), positively charged basic center (orange squares), and positively charged quaternary ammonium (blue diamonds). (B) Percentage reduction in bronchoalveolar eosinophil counts 48 hours after challenge of nonsensitized rats with a natural mixture of HDM allergens following a single aerosolized dose of test substance administered 2 hours prior to allergen challenge. The percentage reduction was calculated relative to vehicle-pretreated animals which underwent similar HDM allergen challenge. Test substances were administered at a drug:target ratio of 50:1 with the exception of compound **11**, tested at 15:1. Data are the mean ± S.E. with 10 animals per treatment group. \**P* \< 0.001 compared with HDM challenge control. Column coloration depicts ionization state of test substance as in (A). (C) Structural information and potency data for compounds used in this study. Full experimental details for chemical syntheses and biologic studies are provided by [@B86] and the online supporting information, <https://pubs.acs.org/doi/suppl/10.1021/jm501102h> and <https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf>. BAL, bronchoalveolar lavage.](mol.118.112730f7){#F7}

As the electrophilic pyruvamide motif has potential for nonspecific interaction with suitable nucleophiles, it was imperative to achieve selectivity over potential off-targets, even though many of these are intracellular and thus intrinsically resilient to reaction compared with the facile extracellular interaction with Der p 1. As already described, the S~3~ pocket of Der p 1 is more capacious than in cathepsins, and our screening campaign confirmed that the steric bulk in this position increased selectivity while retaining potency on target. Inspection of the structural model suggested that the S~2~ pocket of Der p 1 was shallow compared with cathepsin B, K, or S, and so with compact substituents at this position, it was possible to obtain a useful balance of potency and selectivity ([@B86]). As an aside, Blo t 1 exhibits a similar feature at its putative S~2~ pocket, suggesting that compounds designed against a template from a pervasive HDM species may have characteristics which translate to allergens from mites whose evolution has diverged to suit niche environments. Once confidence in the contributions of the P~2~ and P~3~ substituents were obtained, we explored greater variation in the P~4~ and P′ groups, which pleasingly revealed the feasibility of synthesizing compounds, such as **16--21**, of high inhibitory potency and good selectivity consistent with developability ([Fig. 8](#F8){ref-type="fig"}) ([@B86]).

![Further optimization of the P~4~ (R) and P′ groups produces compounds showing high target potency and intrinsic selectivity over cathepsin B. Chemical syntheses and enzymatic activity assays are described by [@B86] and the online supporting information, <https://pubs.acs.org/doi/suppl/10.1021/jm501102h> and <https://pubs.acs.org/doi/suppl/10.1021/jm501102h/suppl_file/jm501102h_si_001.pdf>.](mol.118.112730f8){#F8}

We examined exemplars of optimized compounds in vivo using a variety of readouts to establish confidence in efficacy and duration of protection. These studies confirmed the structural features required for compliance with the exacting candidate drug template and provided test data from which clinical candidates could be selected ([@B86]). A wider examination of the effects of ADIs in experimental models reveals the potential for a fascinating spectrum of effects in the clinic and a profile which is interestingly differentiated from the current standard of care and other entities in development for asthma ([Fig. 9](#F9){ref-type="fig"}; [Table 3](#T3){ref-type="table"}). The overall impression is of an intervention which has the breadth normally associated with corticosteroids. However, ADIs can affect events which are not directly regulated by steroids, and notably, their broad range of effects is achieved without incurring penalties from nonspecific immunosuppression. Pre-eminent in the readouts which show positive effects of ADIs are those strongly associated with events identified by experimental biology as being indispensable in allergy. Some of the signaling entities which drive these indispensable events are now the target of biologic therapies in development. The ability to attenuate the same signals simultaneously by means of an inhaled small molecule provides a superior option with the potential for usage across a broader spectrum of patients.

![Predicted effects profiles for ADIs based on preclinical discovery research models (published and on-file data). (A) Effects of HDM exposure in the airways with a focus on innate immune responses. (B) Example effects of HDM exposure in the presence of ADI drug, with affected pathways grayed out. GMCSF, granulocyte macrophage-colony stimulating factor.](mol.118.112730f9){#F9}

###### 

Potential strategic positioning of ADIs in allergic asthma versus alternative approaches

  Intervention                                                                           Examples                                                                   Remarks
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------------
  Allergen delivery inhibitors                                                           Group 1 HDM protease allergen inhibitors                                   Small molecule
  Inhaled delivery to target organ                                                                                                                                  
  Attractive profile (nonhuman target, extracellular action) with disease modification                                                                              
  Root cause--directed                                                                                                                                              
  Potential to prevent exacerbations                                                                                                                                
  Mechanistic differentiation                                                                                                                                       
  Potential addition to standard of care at all levels of disease severity                                                                                          
  Potentially prescribable at nonspecialist level                                                                                                                   
  Low cost of goods compared with biologics                                                                                                                         
  Exploitable as combination therapy and/or other conditions                                                                                                        
  Alternative small molecules in discovery/development                                   Downstream signal transduction and effector mechanisms---various targets   Uncertain potential to surpass or add significantly to inhaled steroids
  Multiple redundant effector pathways are confounders of efficacy                                                                                                  
  Potentially prescribable at nonspecialist level                                                                                                                   
  Low cost of goods compared with biologics                                                                                                                         
  Biologics---approved or in development                                                 Anticytokine mAbs                                                          High cost of goods
  Antireceptor mAbs                                                                      Mainly applicable to severe disease only                                   
  Anti-IgE mAbs                                                                          Inconvenient to use                                                        
  Anti-IgE vaccine (pAb)                                                                 Multiple redundant pathways are confounders of efficacy                    
                                                                                         High safety barriers (esp. IgE vaccine)                                    
                                                                                         Specialist use only                                                        
                                                                                         Patchy targeting of innate pathways                                        
  Immunotherapy                                                                          Allergen-specific immunotherapy Immune deviation                           Moderately high cost of goods
  Can be inconvenient to use                                                                                                                                        
  Specialists must be involved in GP use                                                                                                                            
  Chronic safety of immune deviation is unproven                                                                                                                    
  Poor targeting of key innate pathways                                                                                                                             

GP, general practitioner; mAb, monoclonal antibody; pAb, polyclonal antibody.

Concluding Remarks {#s19}
==================

From the earliest scientific investigations of allergy, the causative link between allergens and the diseases they produce has attracted attention as a means of disease treatment. The outstanding example of this is the pioneering work of [@B32], which led to the development of allergen immunotherapy and attempted to tolerize the immune system to a particular allergen. However, targets for small-molecule interventions at the root cause level have been nonobvious until recently, so the pharmacotherapy of allergy adopted a different approach which exploited progress in the identification of bioactive mediators and the elucidation of effector mechanisms. The renaissance of innate immunity and an increasing understanding of the molecular basis of allergenicity now creates the first opportunity for pharmacotherapy to target the causative agents of many allergic diseases and thereby prevent the activation of sentinel mechanisms which initiate and sustain disease. In this review, we described progress toward that ambitious objective for what is arguably the most significant of all indoor allergens. The power of the intervention exploits the growing awareness that the allergome is not a molecular democracy: an exclusive cadre of initiator allergens play decisive roles in driving disease. This vulnerability creates a pharmacologic opportunity to exert a broad spectrum of benefits by careful selection of target and chemical design, as exemplified by the pioneer work with ADIs. Naturally, it will be of considerable interest to follow the progression into the clinic of the new drugs from this unique program.
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ADAM

:   A disintegrin and metalloprotease

ADI

:   allergen delivery inhibitor

ADZ 50,000

:   (S)-3-((S)-2-((S)-2-benzamido-3-methylbutanamido)propanamido)-2-oxoheptyl-2,6-bis(trifluoromethyl)benzoate

Blo t

:   *Blomia tropicalis*

CCL

:   C-C chemokine ligand

CD

:   cluster of differentiation

DC

:   dendritic cell

DC-SIGN

:   dendritic cell--specific intercellular adhesion molecule 3--grabbing nonintegrin

Der f

:   *Dermatopagoides farinae*

Der p

:   *Dermatophagoides pteronyssinus*

DPI

:   dry powder inhaler

EMT

:   epithelial-mesenchymal transition

HDM

:   house dust mite

IL

:   interleukin

LPS

:   lipopolysaccharide

MD-2

:   myeloid differentiation protein-2

MRGPR

:   Mas-related G-protein coupled receptor

n

:   native form

Nrf2

:   nuclear factor (erythroid-derived 2)-like 2

PAR

:   protease-activated receptor

r

:   recombinant protein engineering

ROS

:   reactive oxygen species

siRNA

:   small interfering RNA

TAK-242

:   ethyl-(6*R*)-6-(*N*-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate

Th2

:   type 2 T-helper cell

TJ

:   tight junction

TLR

:   Toll-like receptor

TSLP

:   thymic stromal lymphopoietin
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